Hypoxia increases CX3CR1 expression via HIF-1 and NF-κB in androgen-independent prostate cancer cells

International Journal of Oncology

Volumn 41, Issue 5, 2012, Pages 1827-1836

  Xiao, Li Jie ^a,b   Chen, Yuan Yuan ^a   Lin, Ping ^a   Zou, Hai Feng ^a   Lin, Feng ^a   Zhao, Li Nan ^a   Li, Dong ^a   Guo, Liang ^a   Tang, Jie Bing ^a   Zheng, Xiu Lan ^a   Yu, Xiao Guang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG BAYI AGRICULTURAL UNIVERSITY   (China)

Author keywords

CX3CR1; Hypoxia; Hypoxia inducible factor 1 ; Metastasis; Nuclear factor B; Prostate cancer

Indexed keywords

ANDROGEN; CHEMOKINE RECEPTOR CX3CR1; FRACTALKINE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CANCER CELL; CELL HYPOXIA; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GENE SILENCING; HUMAN; HUMAN CELL; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; UPREGULATION;

ANDROGENS; ANOXIA; CELL LINE, TUMOR; CELL MOVEMENT; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MALE; NEOPLASM METASTASIS; NF-KAPPA B; PROSTATIC NEOPLASMS; RECEPTORS, CHEMOKINE;

EID: 84867811185     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1610     Document Type: Article

References (46)

1. Baggiolini M, Dewald B and Moser B: Human chemokines: an update. Annu Rev Immunol 15: 675-705, 1997. (Pubitemid 27169296)
2. Rollins BJ: Chemokines. Blood 90: 909-928, 1997.
3. Goda S, Imai T, Yoshie O, et al: CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and -independent mechanisms. J Immunol 164: 4313-4320, 2000. (Pubitemid 30215094)
4. Bazan JF, Bacon KB, Hardiman G, et al: A new class of membrane-bound chemokine with a CX3C motif. Nature 385: 640-644, 1997.
5. Pan Y, Lloyd C, Zhou H, et al: Neurotactin, a membrane-anchored chemokine upregulated in brain in.ammation. Nature 387: 611-617, 1997. (Pubitemid 27248766)
6. Fong AM, Robinson LA, Steeber DA, et al: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic. ow. J Exp Med 188: 1413-1419, 1998. (Pubitemid 28489578)
7. Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA and Murphy PM: Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 273: 23799-23804, 1998. (Pubitemid 28435714)
8. Imai T, Hieshima K, Haskell C, et al: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91: 521-530, 1997. (Pubitemid 27508241)
9. Nishiyori A, Minami M, Ohtani Y, et al: Localization of fractalkine and CX3CR1 mRNAs in rat brain: does fractalkine play a role in signaling from neuron to microglia? FEBS Lett 429: 167-172, 1998. (Pubitemid 28288203)
10. Jamieson-Gladney WL, Zhang Y, Fong AM, Meucci O and Fatatis A: The chemokine receptor CX3CR1 is directly involved in the arrest of breast cancer cells to the skeleton. Breast Cancer Res 13: R91, 2011.
11. Valdivia-Silva JE, Franco-Barraza J, Silva AL, et al: Effect of pro-inflammatory cytokine stimulation on human breast cancer: implications of chemokine receptor expression in cancer metastasis. Cancer Lett 283: 176-185, 2009.
12. Shulby SA, Dolloff NG, Stearns ME, Meucci O and Fatatis A: CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 64: 4693-4698, 2004. (Pubitemid 38924507)
13. Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O and Fatatis A: CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 68: 1715-1722, 2008. (Pubitemid 351416556)
14. Marchesi F, Piemonti L, Fedele G, et al: The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res 68: 9060-9069, 2008.
15. Nevo I, Sagi-Assif O, Meshel T, et al: The involvement of the fractalkine receptor in the transmigration of neuroblastoma cells through bone-marrow endothelial cells. Cancer Lett 273: 127-139, 2009.
16. Andreasson U, Ek S, Merz H, et al: B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett 259: 138-145, 2008. (Pubitemid 350251646)
17. Erreni M, Solinas G, Brescia P, et al: Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer 46: 3383-3392, 2010.
18. Rodero M, Marie Y, Coudert M, et al: Polymorphism in the microglial cell-mobilizing CX3CR1 gene is associated with survival in patients with glioblastoma. J Clin Oncol 26: 5957-5964, 2008.
19. Gaudin F, Nasreddine S, Donnadieu AC, et al: Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One 6: e21546, 2011.
20. American Cancer Society: Cancer Facts and Figures, 2011. American Cancer Society, Atlanta, 2011.
21. Freedland SJ: Screening, risk assessment, and the approach to therapy in patients with prostate cancer. Cancer 117: 1123-1135, 2011.
22. Ye XC, Choueiri M, Tu SM and Lin SH: Biology and clinical management of prostate cancer bone metastasis. Front Biosci 12: 3273-3286, 2007.
23. Hara T, Miyazaki H, Lee A, Tran CP and Reiter RE: Androgen receptor and invasion in prostate cancer. Cancer Res 68: 1128-1135, 2008. (Pubitemid 351272231)
24. Rudolfsson SH and Bergh A: Hypoxia drives prostate tumour progression and impairs the effectiveness of therapy, but can also promote cell death and serve as a therapeutic target. Expert Opin Ther Targets 13: 219-225, 2009.
25. Palayoor ST, Mitchell JB, Cerna D, Degraff W, John- Aryankalayil M and Coleman CN: PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells. Int J Cancer 123: 2430-2437, 2008.
26. Babar IA, Czochor J, Steinmetz A, Weidhaas JB, Glazer PM and Slack FJ: Inhibition of hypoxia-induced miR-155 radiosensitizes hypoxic lung cancer cells. Cancer Biol Ther 12: 908-914, 2011.
27. Pipinikas CP, Carter ND, Corbishley CM and Fenske CD: HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers 13: 680-691, 2008.
28. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
29. Koong AC, Chen EY and Giaccia AJ: Hypoxia causes the activation of nuclear factor kappa B through the phosphorylation of I kappa B alpha on tyrosine residues. Cancer Res 54: 1425-1430, 1994. (Pubitemid 24106401)
30. Wang Y, L i Z, Z hang H, et al: HIF-1alpha and HIF-2alpha correlate with migration and invasion in gastric cancer. Cancer Biol Ther 10: 376-382, 2010.
31. Balkwill F: The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179, 2004.
32. Murphy PM: Chemokines and the molecular basis of cancer metastasis. N Engl J Med 345: 833-835, 2001.
33. Lu Y, Cai Z, Galson DL, et al: Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66: 1311-1318, 2006. (Pubitemid 44384308)
34. Waugh DJ, Wilson C, Seaton A and Maxwell PJ: Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13: 4595-4604, 2008. (Pubitemid 351589184)
35. Zhang S, Qi L, Li M, et al: Chemokine CXCL12 and its receptor CXCR4 expression are associated with perineural invasion of prostate cancer. J Exp Clin Cancer Res 27: 62, 2008.
36. Gladson CL and Welch DR: New insights into the role of CXCR4 in prostate cancer metastasis. Cancer Biol Ther 7: 1849-1851, 2008.
37. Wang J, Lu Y, Koch AE, Zhang J and Taichman RS: CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Res 68: 10367-10376, 2008.
38. Xiao LJ, Lin P, Lin F, et al: ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. Int J Oncol 40: 1714-1724, 2012.
39. Veldkamp CT, Peterson FC, Hayes PL, et al: On-column refolding of recombinant chemokines for NMR studies and biological assays. Protein Expr Purif 52: 202-209, 2007. (Pubitemid 46038752)
40. Baggiolini M: Chemokines in pathology and medicine. J Intern Med 250: 91-104, 2001.
41. Maxwell PJ, Gallagher R, Seaton A, et al: HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26: 7333-7345, 2007. (Pubitemid 350115971)
42. Wilczynski J, Duechler M and Czyz M: Targeting NF-kappaB and HIF-1 pathways for the treatment of cancer: part I. Arch Immunol Ther Exp (Warsz) 59: 289-299, 2011.
43. Wilczynski J, Duechler M and Czyz M: Targeting NF-kappaB and HIF-1 pathways for the treatment of cancer: part II. Arch Immunol Ther Exp (Warsz) 59: 301-307, 2011.
44. Perkins ND: The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 12: 121-132, 2012.
45. Liu YL, Yu JM, Song XR, Wang XW, Xing LG and Gao BB: Regulation of the chemokine receptor CXCR4 and metastasis by hypoxia-inducible factor in non small cell lung cancer cell lines. Cancer Biol Ther 5: 1320-1326, 2006.
46. Li Y, Qiu X, Zhang S, Zhang Q and Wang E: Hypoxia induced CCR7 expression via HIF-1alpha and HIF-2alpha correlates with migration and invasion in lung cancer cells. Cancer Biol Ther 8: 322-330, 2009.